Integration and Strengthening of the Global Production System, Including the Vietnam Factory
First written in FY2016. 27 of 27 entries say "Advanced", first in FY2016. Latest entry: FY2026.
60 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Capital investment by the Medical Care Solutions Company was ¥36.7 billion. The company invested in construction of a new building at the Kofu Plant to strengthen its production system for contract development and manufacturing of combination products integrating medical devices and pharmaceuticals (CDMO) and other products.」
The company continued to strengthen its production system, including CDMO, and capital investment by the Medical Care Solutions Company, including investment in the new Kofu Plant building, totaled ¥36.7 billion. - FY2026-H1AdvancedAnnual report
「Total assets increased by ¥66.4 billion to ¥1,894.8 billion. This was mainly due to a ¥40.0 billion increase in property, plant and equipment resulting from investment in production facilities and the acquisition of the Leverkusen plant in Germany, and a ¥17.5 billion increase in inventories resulting from business expansion and other factors.」
Property, plant and equipment increased by ¥40.0 billion due to investment in production facilities and the acquisition of the Leverkusen plant in Germany. The strengthening of the global production and CDMO manufacturing infrastructure is also reflected in the company's financial position. - FY2025AdvancedAnnual report
「As of 31 March 2025, the company was proceeding with construction of a new building and other projects at the Kofu Plant to strengthen its CDMO and other production capabilities, with a total investment of ¥58.0 billion and completion scheduled for March 2027.」
The plan to strengthen CDMO and other production capabilities at the Kofu Plant totals ¥58.0 billion, with completion scheduled for March 2027. In FY2025, the Medical Care Solutions Company invested ¥18.5 billion in capital expenditures, while the Blood and Cell Technologies Company invested ¥17.8 billion. - FY2025-H1AdvancedAnnual report
「Cash used in investing activities was ¥38.8 billion, compared with ¥36.1 billion in the same period of the previous year. The main factors were ¥31.7 billion in purchases of property, plant and equipment associated with investments in production facilities and other assets, and ¥6.9 billion in purchases of intangible assets associated with investments in a new IT system and other assets.」
The company made ¥31.7 billion in acquisition expenditures for production facilities and other assets and ¥6.9 billion for a new IT system and other assets, continuing to strengthen its global production network and operating infrastructure. - FY2024AdvancedAnnual report
「Capital investment by the Medical Care Solutions Company was ¥15.6 billion. In addition to investing in construction of a new building at the Kofu Plant to strengthen the production system for contract development and manufacturing of combination products integrating medical devices and pharmaceuticals (Contract Development and Manufacturing Organization, or "CDMO"), the company expanded production capacity and upgraded equipment at the Fujinomiya Plant and Terumo Yamaguchi Co., Ltd. Terumo Yamaguchi Co., Ltd. also began production operations using the expanded CDMO facilities.」
The company continued investing in construction of a new building at the Kofu Plant, and Terumo Yamaguchi began production operations at its expanded CDMO facilities. The total planned investment in the new Kofu Plant building and other projects is ¥52.2 billion, with completion scheduled for March 2027. - FY2024-Q3AdvancedAnnual report
「Cash used in investing activities was ¥53.1 billion, compared with ¥41.9 billion in the same period of the previous year. The main factors were ¥40.4 billion in purchases of property, plant and equipment associated with investments in production facilities and other assets, and ¥13.4 billion in purchases of intangible assets associated with investments in a new IT system and other assets.」
The company invested ¥40.4 billion in production facilities and other assets and ¥13.4 billion in a new IT system and other initiatives, continuing to strengthen its global production and operating infrastructure. - FY2024-Q2AdvancedAnnual report
「The main factors were ¥28.2 billion in purchases of property, plant and equipment associated with investments in production facilities and other assets, and ¥9.7 billion in purchases of intangible assets associated with investments in a new IT system and other assets.」
The company invested ¥28.2 billion in production facilities and other assets and ¥9.7 billion in a new IT system and other initiatives, continuing to strengthen its global production and operating infrastructure. - FY2023AdvancedAnnual report
「In addition, Terumo BCT, Inc. completed construction of the Littleton plant as a new base for its raw-material plasma collection system.」
As part of its global production network, the company completed construction of the U.S. Littleton plant, a new base for its raw-material plasma collection system. It also continued to invest in a new building at the Kofu Plant and strengthen its three-region production network. - FY2023-Q3AdvancedAnnual report
「Cash used in investing activities was ¥41.9 billion, compared with ¥59.3 billion in the same period of the previous year. The main factors were ¥38.0 billion in purchases of property, plant and equipment associated with investments in production facilities and other assets, and ¥14.7 billion in purchases of intangible assets associated with investments in a new IT system and other assets.」
The company invested ¥38.0 billion in production facilities and other assets and ¥14.7 billion in a new IT system and other initiatives, continuing to strengthen its global production and operating infrastructure. - FY2023-Q2AdvancedAnnual report
「At a meeting of the Board of Directors held on 10 November 2022, the company resolved to construct a new factory building at the Kofu Plant in Showa, Nakakoma District, Yamanashi Prefecture, in anticipation of future production increases. The total investment based on this resolution is expected to be ¥30.7 billion.」
To strengthen its global production capabilities, the company resolved to construct a new building at the Kofu Plant and announced an investment plan of ¥30.7 billion. - FY2023-Q1AdvancedAnnual report
「Cash used in investing activities was ¥16.1 billion (¥21.0 billion used in the same period of the previous year). The main factors were ¥11.5 billion in payments for the acquisition of property, plant and equipment associated with investment in production facilities and other assets, and ¥4.2 billion in payments for the acquisition of intangible assets associated with investment in a new IT system and other initiatives.」
During the first quarter, the company invested ¥11.5 billion in production facilities and other assets and ¥4.2 billion in a new IT system and other initiatives, continuing to strengthen its global production and operating infrastructure. - FY2022AdvancedAnnual report
「The company made ¥69.2 billion in capital investment and other investments during the consolidated fiscal year.」
The company invested in production-capacity expansion, equipment upgrades, and facilities related to raw-material plasma collection. Under its major equipment plans, ¥56.484 billion is earmarked for raw-material plasma collection facilities at Terumo BCT, and ¥7.950 billion for expanding Vascular Technologies' production facilities. - FY2022-Q3AdvancedAnnual report
「Cash used in investing activities was ¥59.3 billion (¥63.0 billion used in the same period of the previous year). The main factors were ¥40.8 billion in payments for the acquisition of property, plant and equipment associated with investment in production facilities and other assets, and ¥15.4 billion in payments for the acquisition of intangible assets associated with investment in a new IT system and other initiatives.」
By the cumulative third quarter of FY2022, the company had invested ¥40.8 billion in production facilities and other assets and ¥15.4 billion in a new IT system and other initiatives, continuing to strengthen its global production and operating infrastructure. - FY2022-Q2AdvancedAnnual report
「Cash used in investing activities totaled ¥40.5 billion, compared with ¥44.4 billion in the same period of the previous year. The main factors were ¥27.9 billion in purchases of property, plant and equipment associated with investment in production equipment and other assets, and ¥11.1 billion in purchases of intangible assets associated with investment in a new IT system and other projects.」
During the cumulative FY2022-Q2 period, the company invested ¥27.9 billion in production equipment and other assets and ¥11.1 billion in a new IT system and other projects, continuing to strengthen its production and operating infrastructure. - FY2022-Q1AdvancedAnnual report
「The main factors were ¥14.1 billion in purchases of property, plant and equipment associated with investments in production facilities and other assets, and ¥5.9 billion in purchases of intangible assets associated with investments in a new IT system and other assets.」
During FY2022-Q1, the company spent ¥14.1 billion on production equipment and other assets and ¥5.9 billion on a new IT system and other projects, continuing to strengthen its production and operating infrastructure. - FY2021AdvancedAnnual report
「In addition to capacity expansion at the Ashitaka plant, Terumo Yamaguchi Co., Ltd., Terumo Vietnam Co., Ltd. and MicroVention, Inc., Building 3 at Terumo Vietnam Co., Ltd. was completed.」
Regarding the global production network, including the Vietnam plant, Building 3 at Terumo Vietnam was completed and production capacity was expanded. - FY2021-Q3AdvancedAnnual report
「Cash used in investing activities was ¥63.0 billion, compared with ¥57.1 billion in the same period of the previous year. The main factors were ¥47.4 billion in purchases of property, plant and equipment associated with investments in production facilities and other assets, and ¥15.1 billion in purchases of intangible assets associated with investments in a new IT system and other assets.」
The company invested ¥47.4 billion in production equipment and other assets and ¥15.1 billion in a new IT system and other projects, continuing to strengthen its production network and operating infrastructure. - FY2021-Q2AdvancedAnnual report
「The main factors were ¥32.9 billion in purchases of property, plant and equipment associated with investment in production equipment and other assets, and ¥11.7 billion in purchases of intangible assets associated with investment in a new IT system and other projects.」
During the cumulative FY2021-Q2 period, the company invested ¥32.9 billion in production equipment and other assets and ¥11.7 billion in a new IT system and other projects. It continues to strengthen its global production network and operating infrastructure. - FY2020AdvancedAnnual report
「Capital expenditures by the Cardiovascular Company totaled ¥47.8 billion. In addition to capacity expansion at the Ashitaka plant, Terumo Yamaguchi Co., Ltd., Terumo Vietnam Co., Ltd., MicroVention, Inc. and Vascectech, Ltd., Building 3 at Terumo Yamaguchi was completed.」
To strengthen the global production network, the company invested ¥47.8 billion, mainly through the Cardiovascular Company, and completed Building 3 at Terumo Yamaguchi. Plans including a new building at the Vietnam plant are continuing. - FY2020-Q3AdvancedAnnual report
「¥39.7 billion in purchases of property, plant and equipment associated with construction of a new building at Terumo Yamaguchi Co., Ltd. and other capacity expansion investments」
The company advanced construction of a new building at Terumo Yamaguchi and other capacity expansion investments, with purchases of property, plant and equipment totaling ¥39.7 billion for the cumulative third-quarter period. - FY2020-Q2AdvancedAnnual report
「The main factors were ¥28.0 billion in purchases of property, plant and equipment associated with construction of a new building at Terumo Yamaguchi Co., Ltd. and other capacity expansion investments, and ¥10.8 billion in purchases of intangible assets associated with investment in a new IT system and the acquisition of exclusive distribution rights.」
The company invested ¥28.0 billion in construction of a new building at Terumo Yamaguchi and other capacity expansion investments, and ¥10.8 billion in intangible assets including a new IT system, strengthening its global production and operating infrastructure. - FY2019AdvancedAnnual report
「Terumo Vietnam Co., Ltd. Vietnam plant New building construction Capacity expansion 8,400 - Internal funds September 2019 December 2020」
A new building was planned at the Vietnam-Hanoi plant to expand production capacity, with construction commencing in September 2019, completion scheduled for December 2020 and total planned investment of ¥8.4 billion. - FY2019-Q3AdvancedAnnual report
「The main factors were ¥25.7 billion in purchases of property, plant and equipment and ¥10.9 billion in purchases of intangible assets.」
During the cumulative third-quarter period, the company spent ¥25.7 billion on property, plant and equipment and ¥10.9 billion on intangible assets, advancing capacity expansion and IT investment. - FY2018AdvancedAnnual report
「During the consolidated fiscal year, the company made ¥43.6 billion in capital expenditures and other investments (based on acquisitions of property, plant and equipment and intangible assets; excluding consumption tax and other taxes). Capital expenditures by the Cardiovascular Company totaled ¥20.4 billion, mainly for expanding production capacity at the Ashitaka plant and Terumo Yamaguchi Co., Ltd.」
The company made ¥43.6 billion in capital expenditures and advanced capacity expansion at the Ashitaka plant, Terumo Yamaguchi and Terumo BCT Vietnam. It also plans to construct a new building at the Yamaguchi plant and expand production equipment at the Vascectech headquarters plant. - FY2018-Q3AdvancedAnnual report
「At the production subsidiary in the US territory of Puerto Rico, production of the Angio-Seal hemostasis device had been suspended from 20 September due to the impact of a hurricane, but resumed in November, with shipments beginning in January of Heisei 30.」
Production of Angio-Seal, which had been suspended by a hurricane at the Puerto Rico production subsidiary, resumed in November, and shipments began in January of Heisei 30. - FY2017AdvancedAnnual report
「In production, the company will expand production of disposable products such as blood bags and reduce costs at the Vietnam plant, seeking to improve profitability.」
At the Vietnam plant, expanding production of blood bags and other products and reducing costs were identified as specific measures to improve profitability. - FY2016AdvancedAnnual report
「Integration of the global production network is also progressing steadily, and preparations will continue at the plant near Ho Chi Minh City, Vietnam, for the start of commercial production.」
The preparations for the start of commercial production were specified. Capital expenditures for the period were ¥31.5 billion, including ¥15.5 billion for Cardiovascular, ¥8.5 billion for Hospital and ¥7.2 billion for Blood Systems.